Quick Answer
Adaptimmune Therapeutics PLC reported Stockholders Equity of $11.85 million for fiscal year 2024.
Adaptimmune Therapeutics PLC Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2024 | $11.85M | -70.0% |
| 2023 | $39.51M | -51.7% |
| 2022 | $81.88M | -60.2% |
| 2021 | $205.96M | -39.6% |
| 2020 | $341.23M | +176.0% |
| 2019 | $123.64M | -49.9% |
| 2018 | $246.88M | +21.6% |
| 2017 | $202.98M | +22.2% |
| 2016 | $166.14M | -29.3% |
| 2015 | $234.99M | -9.3% |
| 2015 | $259.00M | +8659.0% |
| 2014 | $2.96M | +237.2% |
| 2013 | -$2.15M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| June 30, 2025 | -$70.96M | -173.7% | -89.6% |
| March 31, 2025 | -$37.43M | -253.6% | -415.9% |
| December 31, 2024 | $11.85M | -70.0% | -85.2% |
| September 30, 2024 | $79.99M | -9.2% | -16.9% |
| June 30, 2024 | $96.27M | -24.0% | +295.0% |
| March 31, 2024 | $24.38M | -70.9% | -38.3% |
| December 31, 2023 | $39.51M | -51.7% | -55.2% |
| September 30, 2023 | $88.13M | -22.2% | -30.4% |
- Adaptimmune Therapeutics PLC showed a decrease of -70.0% in Stockholders Equity compared to the prior fiscal year.
- Over the 2013–2024 period, Adaptimmune Therapeutics PLC’s stockholders equity has grown by 649.8% (from -$2.15 million to $11.85 million).
- The most recent figure is from Adaptimmune Therapeutics PLC’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 24, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: